Johnson & Johnson (JNJ) fundamental analysis

JNJ's fundamentals remain strong, with a 25.74% return on equity (ROE) and 21.48% net profit margin, reflecting efficient capital use and operational excellence. The company generates substantial free cash flow of $16.89 billion, supporting its 1.98% dividend yield and sustainable dividend policy. The forward P/E of 22.34 represents a significant discount to the TTM P/E of 31.50, suggesting market optimism about near-term earnings growth. However, the PEG ratio of 2.84 suggests potential overvaluation relative to growth, requiring careful assessment. JNJ's balance sheet shows moderate leverage with a debt-to-equity ratio of 57.71%, and a current ratio of 1.09, which is acceptable for a large-cap healthcare firm but slightly tight for aggressive short-term credit analysis.